Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The company's leading product candidate has the potential to address the significant unmet medical needs of the large multiple sclerosis (MS) patient population.

Opexa's lead therapy, Tovaxin®, a cellular immunotherapy has completed a Phase 2b clinical study for the treatment of MS which is specifically tailored to each patient's disease profile. Opexa believes the potential combination of efficacy, superior safety, excellent tolerability and administration may position Tovaxin as the MS treatment of choice as compared to existing therapeutics.